Rare diseases
Investigational molecules
Locations
Recruiting trials first
7 clinical trials in this condition
Denmark
Germany
Spain
PolandIn short
Impaired glucose tolerance represents a critical window of opportunity where blood sugar levels sit higher than normal but haven't yet crossed into diabetes territory—a stage where lifestyle changes can genuinely reshape your health future.
When blood sugar levels rise above what's considered healthy but remain below the threshold for a diabetes diagnosis, you're facing a condition that medical professionals call impaired glucose tolerance or impaired fasting glucose. This intermediate state affects somewhere between 10 to 15 percent of adults in the United States, with millions more worldwide navigating this same health challenge. The encouraging news is that this stage isn't a fixed destiny—it's a moment when the right actions can prevent or significantly delay the progression to type 2 diabetes.
Treatment approaches for impaired glucose tolerance focus on returning blood sugar levels to normal ranges and reducing the risk of developing full diabetes. The goals are straightforward: slow or stop the progression to type 2 diabetes, reduce the risk of cardiovascular complications that often accompany elevated blood sugar, and improve overall metabolic health. Unlike diabetes itself, impaired glucose tolerance often causes no symptoms at all, which means many people live with elevated blood sugar for years without realizing it. This silent nature makes screening and early intervention particularly important.
Medical societies and diabetes organizations have established clear guidelines for managing this condition. The treatment path depends on several factors including your current glucose levels, body weight, other health conditions like high blood pressure or elevated cholesterol, family history of diabetes, and your ability to make and maintain lifestyle changes. There are proven standard treatments that doctors recommend first, and there's also ongoing research into new therapeutic approaches being tested in clinical trials around the world.
The cornerstone of treating impaired glucose tolerance is lifestyle modification, which medical studies have repeatedly shown to be more effective than medication alone. When doctors diagnose this condition through blood tests—either a fasting plasma glucose test showing levels between 100 and 125 mg per dL, or a 75-gram oral glucose tolerance test revealing two-hour glucose levels between 140 and 199 mg per dL—the first recommendation is almost always focused on changing daily habits rather than reaching for a prescription pad.
Weight loss stands as one of the most powerful interventions available. Clinical guidelines specifically recommend that patients lose 5 to 7 percent of their body weight. For someone weighing 200 pounds, this means losing just 10 to 14 pounds. This modest reduction might not sound dramatic, but research demonstrates it can significantly reduce the risk of progressing to diabetes. The weight loss works by improving how your body responds to insulin, the hormone responsible for moving sugar from your bloodstream into your cells for energy. When cells become more sensitive to insulin, blood sugar levels naturally decrease.
Physical activity represents another essential element of standard treatment. The American Diabetes Association and other medical organizations recommend at least 150 minutes of moderate physical activity per week. This translates to about 30 minutes of activity on most days of the week. The exercise doesn't need to be intense—brisk walking, swimming, cycling, or even gardening can provide benefits. Physical activity lowers blood sugar in multiple ways: it helps muscles use glucose for energy during and after exercise, increases insulin sensitivity that can last up to 24 hours after a workout, supports weight loss efforts, and improves cardiovascular health which is important since people with impaired glucose tolerance face increased heart disease risk.
Dietary changes form the third pillar of standard treatment. A "clean" diet—one that emphasizes whole, minimally processed foods—can help restore normal blood sugar levels. This approach includes eating more fruits with complex carbohydrates rather than simple sugars, incorporating plenty of vegetables at each meal, choosing lean meats and plant-based proteins, selecting whole grains over refined grains, and including healthy fats from sources like avocados, nuts, and fatty fish. Foods high in fiber are particularly beneficial because fiber slows the absorption of sugar into the bloodstream, preventing sharp spikes in blood glucose. Reducing intake of red meat and heavily processed foods with added sugars and unhealthy fats also helps manage blood sugar levels.
When lifestyle modifications alone aren't sufficient or when patients struggle to implement these changes, medication may be considered. Metformin is the most commonly prescribed drug for impaired glucose tolerance. This medication works by decreasing the amount of glucose your liver produces and improving how your body uses insulin. The Diabetes Prevention Program, a large research study, demonstrated that metformin reduced the risk of developing type 2 diabetes by 31 percent compared to placebo. However, the same study showed that intensive lifestyle changes reduced risk by 58 percent—nearly twice as effective as medication. Metformin is generally well-tolerated, though some people experience gastrointestinal side effects like nausea, diarrhea, or stomach discomfort, especially when first starting the medication.
Another medication that has shown promise is acarbose, which belongs to a class of drugs called alpha-glucosidase inhibitors. Acarbose works differently from metformin—it slows the breakdown and absorption of carbohydrates in your intestines, which prevents blood sugar from rising sharply after meals. Studies have demonstrated that acarbose can delay or prevent the onset of diabetes in people with impaired glucose tolerance. The most common side effects relate to its mechanism of action: because carbohydrates aren't fully broken down in the small intestine, they move to the large intestine where bacteria ferment them, causing gas, bloating, and diarrhea. These effects often improve over time as the body adjusts.
The duration of treatment varies by individual. Lifestyle modifications—healthy eating, regular physical activity, and weight management—are lifelong commitments rather than temporary fixes. These changes need to become permanent parts of daily routine to maintain their benefits. Medication, when prescribed, may be continued long-term if it proves effective and well-tolerated, though doctors regularly reassess whether it remains necessary based on blood sugar monitoring and overall health status.
Additional interventions that complement primary treatment include smoking cessation, as smoking increases diabetes risk and worsens cardiovascular health; moderating alcohol consumption, since excessive drinking can raise blood sugar levels; managing stress through relaxation techniques, adequate sleep, or counseling, because stress hormones can elevate blood glucose; and treating related conditions such as high blood pressure and elevated cholesterol levels, which often occur alongside impaired glucose tolerance as part of metabolic syndrome.
Research into new treatments for impaired glucose tolerance continues actively around the world, with scientists exploring innovative approaches that might offer additional or improved options beyond current standard treatments. Clinical trials test these potential therapies in carefully designed studies that progress through different phases, each with specific goals and safety checks.
Phase I clinical trials focus primarily on safety. In these early studies, researchers test new drugs or interventions in small groups of people to determine safe dosing ranges, identify side effects, and understand how the body processes the treatment. Phase I studies for glucose intolerance treatments typically involve healthy volunteers or people with early metabolic abnormalities to establish basic safety profiles before moving to larger studies.
Phase II clinical trials expand testing to larger groups and focus on efficacy—whether the treatment actually works to improve glucose tolerance. These studies typically enroll people who have been diagnosed with impaired glucose tolerance through standard blood tests. Researchers measure outcomes like fasting glucose levels, results on oral glucose tolerance tests, insulin sensitivity, and markers of inflammation that contribute to metabolic dysfunction. Phase II trials help determine the optimal dose and provide preliminary evidence about effectiveness before proceeding to the larger, more expensive Phase III studies.
Phase III clinical trials compare new treatments against standard care or placebo in much larger populations, often involving hundreds or thousands of participants across multiple locations. For impaired glucose tolerance, these studies might compare a new medication against metformin or against lifestyle intervention alone. Phase III trials provide the definitive evidence needed for regulatory approval and establish whether a treatment offers meaningful benefits in real-world settings.
One promising area of research involves incretin mimetics, medications that work with your body's natural hormone systems. Exenatide and liraglutide are examples of these drugs—they mimic the action of GLP-1 (glucagon-like peptide-1), a hormone released after eating that stimulates insulin secretion, suppresses glucagon (which raises blood sugar), slows stomach emptying, and promotes feelings of fullness. These medications have been approved for treating type 2 diabetes and have shown promise in preventing diabetes progression. They work by multiple mechanisms: stimulating insulin release in response to meals, inhibiting glucagon secretion which would otherwise raise blood sugar, delaying how quickly food leaves the stomach which prevents sharp glucose spikes, and inducing early satiety which supports weight loss efforts. Research suggests these drugs may also help preserve the insulin-producing cells in the pancreas, potentially slowing the underlying disease process.
Another class of medications being studied are DPP-4 inhibitors such as sitagliptin and vildagliptin. These drugs work by blocking an enzyme called dipeptidyl peptidase-4, which normally breaks down the body's natural GLP-1 hormone. By inhibiting this enzyme, DPP-4 inhibitors allow GLP-1 levels to remain higher for longer periods, improving blood sugar control. The advantages of these medications include that they're taken orally rather than by injection, they're generally well-tolerated with few side effects, and they don't typically cause weight gain—an important consideration since weight management is crucial for people with impaired glucose tolerance. Clinical studies have demonstrated their effectiveness in improving glucose metabolism and they're being investigated for preventing progression to diabetes.
Pramlintide acetate represents another innovative approach. This medication contains an analogue of amylin, a hormone normally produced by the same pancreatic cells that make insulin. Amylin is released along with insulin after meals and helps regulate glucose by slowing stomach emptying, suppressing post-meal glucagon release, and promoting satiety. In people with impaired glucose tolerance, amylin regulation may be disrupted. Pramlintide aims to replace or supplement amylin function, improving blood sugar control after meals. This medication is administered by injection and clinical trials are exploring whether it can help prevent diabetes in high-risk individuals.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a different therapeutic strategy. These medications work in the kidneys, blocking the reabsorption of glucose so that excess sugar is eliminated in urine rather than returning to the bloodstream. While currently approved for treating diabetes, researchers are investigating whether SGLT2 inhibitors might benefit people with impaired glucose tolerance by reducing blood sugar burden through this unique mechanism. Early research shows potential benefits for weight loss and blood pressure reduction alongside glucose lowering effects.
Some clinical trials are exploring botanical compounds and dietary supplements that may improve glucose metabolism. These include plant extracts that might enhance insulin sensitivity, reduce glucose absorption from the intestines, or provide antioxidant benefits that protect cells involved in glucose regulation. However, research on botanicals remains in earlier stages, and more rigorous clinical trials are needed before definitive recommendations can be made about their effectiveness and safety. The regulation of supplements differs from pharmaceutical drugs, which means quality and potency can vary between products, making standardized research challenging.
Combination therapies are also being investigated—using two or more treatments together that work through different mechanisms. For example, combining lifestyle intervention with medication, or using two medications that complement each other's effects. The rationale is that addressing multiple aspects of glucose metabolism simultaneously might produce better results than single interventions alone.
Clinical trials for glucose intolerance treatments are conducted in various locations worldwide, including the United States, Europe, Asia, and other regions. Eligibility for participation typically requires confirmed diagnosis of impaired glucose tolerance through blood testing, being within certain age ranges, having no contraindications to the specific treatment being studied, and willingness to attend regular study visits for monitoring. People interested in clinical trials can discuss options with their healthcare providers or search trial registries to find studies accepting participants in their area.
While preliminary results from many of these studies show promise—improvements in glucose tolerance test results, reductions in fasting glucose levels, positive safety profiles with manageable side effects, and in some cases prevention of progression to diabetes—it's important to remember that clinical trials are research. Not all promising early results lead to approved treatments, and what works in controlled trial conditions may differ from real-world effectiveness. The benefit of standard lifestyle modifications remains the proven, most effective approach currently available.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
